Xspray Pharma
Develops improved cancer drugs (PKIs) using a patented amorphous formulation technology.
XSPRAY | ST
Overview
Corporate Details
- ISIN(s):
- SE0009973563 (+3 more)
- LEI:
- 549300NGRQCNZ3X4L157
- Country:
- Sweden
- Address:
- Scheeles väg 2, 171 65 Solna
- Website:
- https://xspraypharma.com/
- Sector:
- Manufacturing
Description
Xspray Pharma is a pharmaceutical company that utilizes its patented technology platform to develop improved versions of marketed drugs, primarily focusing on Protein Kinase Inhibitors (PKIs) for cancer treatment. The company's core innovation lies in its ability to create stable, amorphous (non-crystalline) formulations of active pharmaceutical ingredients. This unique approach enables the development of product candidates that can bypass the secondary patents of original crystalline drugs, facilitating market entry upon the expiration of the primary substance patent. Xspray Pharma's products are designed to offer clinical benefits for patients compared to the original branded drugs and their subsequent generic equivalents.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-25 16:45 |
Xspray erhåller ytterligare teckningsåtaganden om 20 MSEK i den pågående företr…
|
Swedish | 61.1 KB | ||
| 2025-08-15 08:00 | Swedish | 1018.3 KB | |||
| 2025-08-15 08:00 | English | 1020.5 KB | |||
| 2025-08-15 07:50 |
Xspray beslutar om en företrädesemission om cirka 130 MSEK med en övertilldelni…
|
Swedish | 77.5 KB | ||
| 2025-08-15 07:50 |
Xspray resolves on a rights issue of approximately SEK 130 million with an over…
|
English | 77.5 KB | ||
| 2025-08-12 08:18 |
Xspray Pharma tecknar licensavtal med Handa Therapeutics – erhåller upp till tv…
|
Swedish | 44.4 KB | ||
| 2025-08-12 08:18 |
Xspray Pharma signs license agreement with Handa Therapeutics – to receive up t…
|
English | 44.2 KB | ||
| 2025-07-11 14:10 |
XSpray Pharma achieves significant milestone – demonstrating bioequivalence wit…
|
English | 45.6 KB | ||
| 2025-07-11 14:10 |
XSpray Pharma uppnår betydande milstolpe – visar bioekvivalens med absorptionsf…
|
Swedish | 45.8 KB | ||
| 2025-06-27 15:55 |
Xspray Pharma Passes FDA Pre-Approval Inspection – Key Regulatory Milestone Ach…
|
English | 44.2 KB | ||
| 2025-06-27 15:55 |
Xspray Pharma Klarar FDA:s Pre-Approval Inspection – Viktig Regulatorisk Milsto…
|
Swedish | 43.9 KB | ||
| 2025-05-14 21:10 |
FDA meddelar PDUFA-datum för Xspray Pharmas kompletterade ansökan för Dasynoc®
|
Swedish | 44.6 KB | ||
| 2025-05-14 21:10 |
FDA sets PDUFA-date for Xspray Pharma's re-submitted application for Dasynoc®
|
English | 44.1 KB | ||
| 2025-05-13 11:03 |
Kommuniké från årsstämma i Xspray Pharma AB (publ)
|
Swedish | 45.5 KB | ||
| 2025-05-13 11:03 |
Bulletin from the annual general meeting of Xspray Pharma AB (publ)
|
English | 44.2 KB |
Automate Your Workflow. Get a real-time feed of all Xspray Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xspray Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xspray Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-10 | Anders Ekblom | Other | Buy | 168,000 | 4,998,000.00 SEK |
| 2024-06-04 | Ribbskottet AB Anders Bladh | Other | Buy | 1,958 | 145,655.62 SEK |
| 2024-06-03 | Anders Bladh, Ribbskottet | Other | Buy | 3,042 | 225,077.58 SEK |
| 2024-05-29 | Per Andersson | Other | Buy | 51,749 | 489,545.54 SEK |
| 2024-05-27 | Per Andersson | Other | Sell | 9,950 | 687,545.00 SEK |
| 2024-05-16 | Anders Bladh | Other | Buy | 10,000 | 503,500.00 SEK |
| 2024-05-02 | Maris Hartmanis | Other | Other | 2,385 | 95,400.00 SEK |
| 2024-05-02 | Christine Lind | Other | Other | 666 | 26,640.00 SEK |
| 2024-05-02 | Anders Ekblom | Other | Other | 500 | 20,000.00 SEK |
| 2024-03-05 | Robert Molander | Other | Buy | 5,000 | 20,000.00 USD |
Peer Companies
